Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

MACOP-B regimen

Known as: Methotrexate-Adriamycin-Cytoxan-Oncovin-Prednisone-Bleomycin Regimen 
A regimen consisting of methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine and prednisone, used to treat aggressive forms of non… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2007
2007
BACKGROUND AND OBJECTIVES Common methylenetetrahydrofolate reductase gene variants (MTHFR C677T and A1298C) have been described… Expand
Is this relevant?
2007
2007
Loss of major histocompatibility class II (MHC class II) molecules on diffuse large B-cell lymphoma (DLBCL) has been associated… Expand
Is this relevant?
Highly Cited
2004
Highly Cited
2004
The optimal treatment of primary mediastinal large B-cell lymphoma (PMLBCL) is still undefined. In the absence of randomised… Expand
  • figure 1
  • table 3
  • table 1
  • table 2
  • figure 2
Is this relevant?
Highly Cited
1999
Highly Cited
1999
To evaluate the efficacy of a combined modality treatment (MACOP-B plus mediastinal radiotherapy) and the advantages of Gallium… Expand
  • table 2
  • table 1
  • table 3
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
1997
Highly Cited
1997
BACKGROUND We compared a regimen of six chemotherapeutic agents administered sequentially at high doses, followed by… Expand
Is this relevant?
1994
1994
PURPOSE To compare complete response rates, time to failure, survival, and toxicity for patients with intermediate-grade non… Expand
Is this relevant?
Highly Cited
1993
Highly Cited
1993
BACKGROUND CHOP is a first-generation, combination-chemotherapy regimen consisting of cyclophosphamide, doxorubicin, vincristine… Expand
Is this relevant?
1992
1992
PURPOSE The prognosis of advanced-stage diffuse large-cell lymphoma (DLCL) has improved with the use of the third-generation… Expand
Is this relevant?
Highly Cited
1990
Highly Cited
1990
While diffuse large-cell lymphoma (DLCL) is considered to be highly curable with current therapy, treatment failures are observed… Expand
  • table 1
  • table 2
  • figure 1
  • table 3
  • figure 2
Is this relevant?
Highly Cited
1985
Highly Cited
1985
Between April 1981 and May 1984, 61 patients with advanced diffuse large-cell lymphoma completed treatment with MACOP-B… Expand
Is this relevant?